Vistagen Announces Results Of U.S. Phase 1 Study Of Itruvone, Enabling U.S. Phase 2B Development For Treatment Of Major Depressive Disorder
Portfolio Pulse from Happy Mohamed
Vistagen announces favorable safety and tolerability data from its U.S. Phase 1 clinical trial of itruvone (PH10), a rapid-onset pherine nasal spray for the treatment of major depressive disorder (MDD). The results enable Phase 2B development of itruvone in the U.S.
June 21, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vistagen's itruvone (PH10) shows positive results in U.S. Phase 1 trial, enabling Phase 2B development for the treatment of major depressive disorder.
The positive results from the U.S. Phase 1 trial of itruvone (PH10) indicate that the treatment is safe and well-tolerated, which is crucial for further development and potential approval. This news is likely to have a positive impact on Vistagen's stock price in the short term as it demonstrates progress in the company's pipeline and brings it closer to potentially having a new treatment for major depressive disorder.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100